2,777 reports of this reaction
3.2% of all NINTEDANIB reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for NINTEDANIB, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 2,777 FDA adverse event reports linking NINTEDANIB to FATIGUE. This represents approximately 3.2% of all 85,660 adverse event reports for this drug.
NINTEDANIB has an overall safety score of 85 out of 100. Patients taking NINTEDANIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among NINTEDANIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for NINTEDANIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,777 FDA reports for NINTEDANIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.2% of all adverse event reports for NINTEDANIB, making it a notable side effect.
If you experience fatigue while taking NINTEDANIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.